The Multinational Association for Supportive Care in Cancer Score (MASCC Score) can identify patients with malignant tumors who have a low risk of complications during febrile neutropenia.

A score ≥ 21 indicates low-risk patients, with a specificity of 68% and a sensitivity of 71%.